Challenges in Assessing Dose-Dependent Atropine for Myopia—Reply

Yong Li,Audrey Chia,Marcus Ang

DOI: https://doi.org/10.1001/jamaophthalmol.2024.3078

IF: 8.253

2024-09-21

JAMA Ophthalmology

Abstract:In Reply We agree that long-term studies evaluating adults who had childhood myopia control are challenging but needed. Our study showed no statistical difference in final refraction between groups at recall. 1 We do not believe that high doses worsen final refractive errors. Patients receiving higher doses progressed less, on average, during treatment but were more likely to rebound during washout, associated with a greater likelihood of a loss in the treatment benefit (Figure). Some differences remained in ATOM2 participants, with those receiving higher doses possibly having slightly worse outcome. It is possible that if treatment had been continued longer, or rebound managed better, the outcome could have been different. The presence of myopia-related complications was low and appeared to be more likely associated with end refraction than with atropine dose.

ophthalmology